# Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers

> **NCT00233337** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Acute Uncomplicated P. Falciparum Malaria

## Interventions

- **DRUG:** Co-artemether

## Key facts

- **NCT ID:** NCT00233337
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** — (—)
- **Last updated:** 2012-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233337, "Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00233337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*